Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds

[cafead]

via Sanofi’s first-quarter update brought bad news for drug candidates acquired in buyouts worth $8 billion, with the French drugmaker removing Ablynx and Principia Biopharma molecules from its pipeline after getting a look at clinical data.

article source